In the last trading session, 2.81 million shares of the Denali Therapeutics Inc (NASDAQ:DNLI) were traded, and its beta was 1.55. Most recently the company’s share price was $15.95, and it changed around $0.75 or 4.93% from the last close, which brings the market valuation of the company to $2.32B. DNLI currently trades at a discount to its 52-week high of $33.33, offering almost -108.97% off that amount. The share price’s 52-week low was $14.56, which indicates that the current value has risen by an impressive 8.71% since then.
Denali Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.18. If we narrow it down even further, the data shows that 0 out of 19 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended DNLI as a Hold, whereas 14 deemed it a Buy, and 0 rated it as Underweight. Denali Therapeutics Inc is expected to report earnings per share of -0.7 for the current quarter.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Instantly DNLI has showed a green trend with a performance of 4.93% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 19.66 on recent trading dayincreased the stock’s daily price by 18.87%. The company’s shares are currently down -21.74% year-to-date, but still down -16.93% over the last five days. On the other hand, Denali Therapeutics Inc (NASDAQ:DNLI) is -31.55% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $38.5, which translates to bulls needing to increase their stock price by 58.57% from its current value. Analyst projections state that DNLI is forecast to be at a low of $32 and a high of $45.
9 analysts expect Denali Therapeutics Inc to make 5.56M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -4.46%. Denali Therapeutics Inc earnings are expected to increase by -9.52% in 2025, but the outlook is positive 8.94% per year for the next five years.
DNLI Dividends
Denali Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
BAILLIE GIFFORD & CO, with 8.1523% or 13.76 million shares worth $319.59 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
